Science

Mar 15, 2025, 09:06

Myeloma Paper of the Day, March 15th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of patient-reported outcomes and survival and adverse events in daratumumab-treated myeloma finds (surprisingly!) low physical function patients experienced greater OS and PFS benefit.”

“Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma”

Authors: Ahmad Abuhelwa, Sara Almansour, Ethan Basch, Humaid Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad Semreen, Zelal Kharaba, Salma Ali, Rawan Mohamed, Ganessan Kichenadasse, Ross McKinnon, Michael Sorich, Karem Alzoubi, Ashley Hopkins.

More posts featuring Robert Orlowski.

Ahmad Abuhelwa Ashley Hopkins cancer daratumumab-treated myeloma Ethan Basch Ganessan Kichenadasse Humaid Al-Shamsi Karem Alzoubi Michael Sorich multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Ross McKinnon Sara Almansour Ziad Abuhelwa

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research

Stella Kyriakides joins ESO as Co-Chair and Senior Lecturer in Cancer Policy to Guide the 2026–2028 Strategic Plan